Drug intelligence / Profile preview

LK@BCCR-FP

Development stage: Preclinical
Modality: Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**LK@BCCR-FP** is an experimental, orally delivered nanozyme-armored probiotic platform developed for synchronous treatment of ulcerative colitis and sepsis in mouse models. It comprises *Lactobacillus kefiranofaciens* loaded with a boronic acid chitosan-modified nanozyme core and coated with a Fu brick tea polysaccharide prebiotic shell. The platform is designed to localize at inflamed colonic mucosa, scavenge reactive oxygen species, support probiotic viability and colonization, remodel gut microbial and metabolic homeostasis, restore intestinal-barrier integrity, and reduce lipopolysaccharide translocation. In DSS-induced colitis mice, it activated Nrf2-associated antioxidant signaling and reduced p53/caspase-3-associated epithelial apoptosis; in LPS-induced sepsis mice, it reduced systemic inflammatory-metabolic disturbances and extraintestinal organ injury.

Other names: LK@BCCR-FP

Beyond the preview

Go deeper on LK@BCCR-FP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LK@BCCR-FP.

Explore the full profile